Research ExplorerPublicationsFrequent high-level expression of the immunotherapeutic targ...

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

Standard

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. / Went, P; Vasei, M; Bubendorf, L; Terracciano, L; Tornillo, L; Riede, U; Kononen, J; Simon, Ronald; Sauter, Guido; Baeuerle, P A.

In: BRIT J CANCER, Vol. 94, No. 1, 1, 2006, p. 128-135.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Went, P, Vasei, M, Bubendorf, L, Terracciano, L, Tornillo, L, Riede, U, Kononen, J, Simon, R, Sauter, G & Baeuerle, PA 2006, 'Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.', BRIT J CANCER, vol. 94, no. 1, 1, pp. 128-135. <http://www.ncbi.nlm.nih.gov/pubmed/16404366?dopt=Citation>

APA

Went, P., Vasei, M., Bubendorf, L., Terracciano, L., Tornillo, L., Riede, U., Kononen, J., Simon, R., Sauter, G., & Baeuerle, P. A. (2006). Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. BRIT J CANCER, 94(1), 128-135. [1]. http://www.ncbi.nlm.nih.gov/pubmed/16404366?dopt=Citation

Vancouver

Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. BRIT J CANCER. 2006;94(1):128-135. 1.

Bibtex

@article{779cab36b85241439d8dc743aefd709b,
title = "Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.",
abstract = "Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival. We analysed by immunohistochemical staining tissue microarrays with 4046 primary human carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under highly standardised conditions. A total of 3360 samples were analysable. High-level Ep-CAM expression was observed in 97.7% (n=1186) of colon, 90.7% of gastric (n=473), and 87.2% of prostate cancers (n=414), and in 63.9% of lung cancers (n=1287). No detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers. The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM expression on grade 3 tumours was down to 92.1% (P",
author = "P Went and M Vasei and L Bubendorf and L Terracciano and L Tornillo and U Riede and J Kononen and Ronald Simon and Guido Sauter and Baeuerle, {P A}",
year = "2006",
language = "Deutsch",
volume = "94",
pages = "128--135",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

AU - Went, P

AU - Vasei, M

AU - Bubendorf, L

AU - Terracciano, L

AU - Tornillo, L

AU - Riede, U

AU - Kononen, J

AU - Simon, Ronald

AU - Sauter, Guido

AU - Baeuerle, P A

PY - 2006

Y1 - 2006

N2 - Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival. We analysed by immunohistochemical staining tissue microarrays with 4046 primary human carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under highly standardised conditions. A total of 3360 samples were analysable. High-level Ep-CAM expression was observed in 97.7% (n=1186) of colon, 90.7% of gastric (n=473), and 87.2% of prostate cancers (n=414), and in 63.9% of lung cancers (n=1287). No detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers. The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM expression on grade 3 tumours was down to 92.1% (P

AB - Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival. We analysed by immunohistochemical staining tissue microarrays with 4046 primary human carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under highly standardised conditions. A total of 3360 samples were analysable. High-level Ep-CAM expression was observed in 97.7% (n=1186) of colon, 90.7% of gastric (n=473), and 87.2% of prostate cancers (n=414), and in 63.9% of lung cancers (n=1287). No detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers. The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM expression on grade 3 tumours was down to 92.1% (P

M3 - SCORING: Zeitschriftenaufsatz

VL - 94

SP - 128

EP - 135

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 1

M1 - 1

ER -